Document:

Exhibit 10.4

 

NEITHER
THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

(WARRANT
B)

 

BRAIN
SCIENTIFIC, INC.

 

Warrant
Shares: 705,882

Date
of Issuance: September 22, 2020 (“Issuance Date”)

 

This
COMMON STOCK PURCHASE WARRANT (WARRANT B) (the “Warrant”) certifies that, for value received (in connection
with the issuance of the $600,000.00 aggregate amount of convertible promissory note to the Holder (as defined below) of even
date) (the “Note”), Auctus Fund, LLC, a Delaware limited liability company (including any permitted and registered
assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and
the conditions hereinafter set forth, at any time on or after the issuance hereof, to purchase from BRAIN SCIENTIFIC, Inc., a
Nevada corporation (the “Company”), up to 705,882 shares of Common Stock (as defined below) (the “Warrant
Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant)
at the Exercise Price per share then in effect. This Warrant is issued by the Company as of the date hereof in connection with
that certain securities purchase agreement dated September 22, 2020, by and among the Company and the Holder (the “Purchase
Agreement”).

 

Capitalized
terms used in this Warrant shall have the meanings set forth in the Purchase Agreement unless otherwise defined in the body of
this Warrant or in Section 12 below. For purposes of this Warrant, the term “Exercise Price” shall mean $1.28,
subject to adjustment as provided herein (including but not limited to cashless exercise), and the term “Exercise
Period” shall mean the period commencing at any time on or after the date hereof and ending on 5:00 p.m., eastern standard
time on the three-year anniversary thereof. NOTWITHSTANDING THE FOREGOING, IN THE EVENT THE COMPANY REPAYS THE NOTE IN ITS ENTIRETY
ON OR PRIOR TO THE MATURITY DATE OF THE NOTE, THIS WARRANT SHALL AUTOMATICALLY EXPIRE, AND THIS WARRANT MAY ONLY BE EXERCISED
IN THE EVENT IT DOES NOT SO AUTOMATICALLY EXPIRE.

 

     

     

    

 

1. EXERCISE
OF WARRANT.

 

(a) Mechanics
of Exercise. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in whole
or in part at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto as Exhibit
A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant. The Holder shall not
be required to deliver the original Warrant in order to effect an exercise hereunder. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. On or
before the second Trading Day (the “Warrant Share Delivery Date”) following the date on which the Holder sent
the Exercise Notice to the Company or the Company’s transfer agent, and upon receipt by the Company of payment to the Company
of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which all or a portion of
this Warrant is being exercised (the “Aggregate Exercise Price” and together with the Exercise Notice, the
“Exercise Delivery Documents”) in cash or by wire transfer of immediately available funds (or by cashless exercise,
in which case there shall be no Aggregate Exercise Price provided), the Company shall (or direct its transfer agent to) issue
and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s
share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise (or deliver such shares of Common Stock in electronic format if requested by the Holder). Upon delivery
of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record
of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates
evidencing such Warrant Shares. If this Warrant is submitted in connection with any exercise and the number of Warrant Shares
represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise,
then the Company shall as soon as practicable and in no event later than three Business Days after any exercise and at its own
expense, issue a new Warrant (in accordance with Section 6) representing the right to purchase the number of Warrant Shares purchasable
immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is
exercised.

 

If
the Company fails to cause its transfer agent to transmit to the Holder the respective shares of Common Stock by the respective
Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise in Holder’s sole discretion, and
such failure shall be deemed an event of default under the Note.

 

If
(i) the Market Price of one share of Common Stock is greater than the Exercise Price and (ii) the Warrant Shares are not registered
for resale by the Company pursuant to an effective registration statement under the Securities Act of 1933, as amended on or prior
to the 6th monthly anniversary of the Issuance Date, then the Holder may elect to receive Warrant Shares pursuant to
a cashless exercise, in lieu of a cash exercise, equal to the value of this Warrant determined in the manner described below (or
of any portion thereof remaining unexercised) by surrender of this Warrant and a Notice of Exercise, in which event the Company
shall issue to Holder a number of Common Stock computed using the following formula:

 

X
= Y (A-B)

 

A

 

	 	Where	X =	the number of Shares to be issued to Holder.
	 	 
	 	 	Y =	the number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date of such calculation).
	 	 
	 	 	A =	 the Market Price (at the date of such calculation).
	 	 
	 	 	B =	 Exercise Price (as adjusted to the date of such calculation).

 

(b) No
Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment
pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes
of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise
would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder
otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then-current fair market
value of a Warrant Share by such fraction.

 

    2

     

    

 

(c) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, to the extent that after giving effect to issuance of Warrant Shares upon exercise as set
forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other persons acting
as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial
Ownership Limitation, as defined below. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially
owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant
with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned by the Holder or any of
its Affiliates and (ii) exercise or conversion of the unexercised or non-converted portion of any other securities of the Company
(including without limitation any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous
to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding
sentence, for purposes of this paragraph (d), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is
in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed
in accordance therewith. To the extent that the limitation contained in this paragraph applies, the determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of which portion
of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned
by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.

 

For
purposes of this paragraph, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the
Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the
Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the request of a Holder, the
Company shall within two Trading Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its affiliates since the date as of which such number of outstanding
shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of
shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
exercise of this Warrant. The limitations contained in this paragraph shall apply to a successor Holder of this Warrant.

 

2. ADJUSTMENTS.
The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

 

(a) Distribution
of Assets. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its
assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation any distribution
of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement
or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in
each such case:

 

(i) any
Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders
of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such
record date, to a price determined by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing
Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution
(as determined in good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the
denominator of which shall be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such
record date; and

 

    3

     

    

 

(ii) the
number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to
receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause (i); provided,
however, that in the event that the Distribution is of shares of common stock of a company (other than the Company) whose common
stock is traded on a national securities exchange or a national automated quotation system (“Other Shares of Common Stock”),
then the Holder may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of an increase in the number of
Warrant Shares, the terms of which shall be identical to those of this Warrant, except that such warrant shall be exercisable
into the number of shares of Other Shares of Common Stock that would have been payable to the Holder pursuant to the Distribution
had the Holder exercised this Warrant immediately prior to such record date and with an aggregate exercise price equal to the
product of the amount by which the exercise price of this Warrant was decreased with respect to the Distribution pursuant to the
terms of the immediately preceding clause (i) and the number of Warrant Shares calculated in accordance with the first part of
this clause (ii).

 

(b) Anti-Dilution
Adjustments to Exercise Price. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is
outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue
(or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or securities entitling any
person or entity to acquire shares of Common Stock (upon conversion, exercise or otherwise) (including but not limited to under
the Note), at an effective price per share less than the then Exercise Price (such lower price, the “Base Share Price”
and such issuances collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock
Equivalents so issued shall at any time, whether by operation of purchase price adjustments, elimination of an applicable floor
price for any reason in the future (including but not limited to the passage of time or satisfaction of certain condition(s)),
reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share
which are issued in connection with such issuance, be entitled or potentially entitled to receive shares of Common Stock at an
effective price per share which is less than the Exercise Price at any time while such Common Stock or Common Stock Equivalents
are in existence, such issuance shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive
Issuance (regardless of whether the Common Stock, Common Stock Equivalents, or Note are (i) subsequently redeemed or retired by
the Company after the date of the Dilutive Issuance or (ii) actually converted or exercised at such Base Share Price), then the
Exercise Price shall be reduced at the option of the Holder and only reduced to equal the Base Share Price, and the number of
Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise Price payable hereunder, after taking into
account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior to such adjustment (for the avoidance
of doubt, the aggregate Exercise Price prior to such adjustment is calculated as follows: the total number of Warrant Shares issuable
upon exercise of this Warrant immediately prior to such adjustment (without regard to the Beneficial Ownership Limitation) multiplied
by the Exercise Price in effect immediately prior to such adjustment). By way of example, if E is the total number of Warrant
Shares issuable upon exercise of this Warrant immediately prior to such adjustment (without regard to the Beneficial Ownership
Limitation), F is the Exercise Price in effect immediately prior to such adjustment, and G is the Base Share Price, the adjustment
to the number of Warrant Shares can be expressed in the following formula: Total number of Warrant Shares after such Dilutive
Issuance = the number obtained from dividing [E x F] by G. Such adjustment shall be made whenever such Common Stock or Common
Stock Equivalents are issued; provided, however, that in the event any such Dilutive Issuance is not so converted and either expires
in accordance with its terms or is repaid in cash (as the case may be), the Exercise Price shall revert back to what it was without
taking into account this sub-paragraph (b) as it relates to such Dilutive Issuance.. The Company shall notify the Holder in writing,
no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 2(b),
indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing
terms (such notice the “Dilutive Issuance Notice”). For purposes of clarification, whether or not the Company
provides a Dilutive Issuance Notice pursuant to this Section 2(b), upon the occurrence of any Dilutive Issuance, after the date
of such Dilutive Issuance (but subject to the terms hereof) the Holder is entitled to receive a number of Warrant Shares based
upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise.
The issuance of Common Stock at an issuance price below the Exercise Price as a result of conversions by the Holder of the $600,000
aggregate principal amount convertible note issued to the Holder by the Company on September 22, 2020 shall be excluded from the
definition of a Dilutive Issuance. This Section 2(b) shall no longer apply or have any force or effect if and upon the Company’s
Common Stock being listed for trading on the Nasdaq National Market, Nasdaq Small Cap Market, New York Stock Exchange, NYSE MKT
or other national securities exchange.

 

    4

     

    

 

(c) Subdivision
or Combination of Common Stock. If the Company at any time on or after the Issuance Date subdivides (by any stock split, stock
dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of
shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant
Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines (by combination, reverse
stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise
Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will
be proportionately decreased. Any adjustment under this Section 2(c) shall become effective at the close of business on the date
the subdivision or combination becomes effective. Each such adjustment of the Exercise Price shall be calculated to the nearest
one-hundredth of a cent. Such adjustment shall be made successively whenever any event covered by this Section 2(c) shall occur.

 

3. FUNDAMENTAL
TRANSACTIONS. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company with or
into another entity and the Company is not the surviving entity (such surviving entity, the “Successor Entity”),
(ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii)
any tender offer or exchange offer (whether by the Company or by another individual or entity, and approved by the Company) is
completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares of Common Stock for other
securities, cash or property and the holders of at least 50% of the Common Stock accept such offer, or (iv) the Company effects
any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of
Common Stock) (in any such case, a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant,
the Holder shall have the right to receive the number of shares of Common Stock of the Successor Entity or of the Company and
any additional consideration (the “Alternate Consideration”) receivable upon or as a result of such reorganization,
reclassification, merger, consolidation or disposition of assets by a holder of the number of shares of Common Stock for which
this Warrant is exercisable immediately prior to such event (disregarding any limitation on exercise contained herein solely for
the purpose of such determination). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share
of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of
Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the
Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following
such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any Successor Entity in such Fundamental
Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s
right to exercise such warrant into Alternate Consideration.

 

4. NON-CIRCUMVENTION.
The Company covenants and agrees that it will not, by amendment of its certificate of incorporation, bylaws or through any reorganization,
transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good
faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder.
Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock
receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of Common
Stock upon the exercise of this Warrant, and (iii) shall, for so long as this Warrant is outstanding, have authorized and reserved,
free from preemptive rights, ten times the number of shares of Common Stock that is actually issuable upon full exercise of the
Warrant (based on the Exercise Price in effect from time to time, and without regard to any limitations on exercise).

 

    5

     

    

 

5. WARRANT
HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, this Warrant, in and of itself, shall not
entitle the Holder to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained in this
Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant
or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the
Company.

 

6. REISSUANCE.

 

(a) Lost,
Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as to
indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

(b) Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant which
is the same as the Issuance Date.

 

7. TRANSFER.
This Warrant shall be binding upon the Company and its successors and assigns, and shall inure to be the benefit of the Holder
and its successors and assigns. Notwithstanding anything to the contrary herein, the rights, interests or obligations of the Company
hereunder may not be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior signed
written consent of the Holder, which consent may be withheld at the sole discretion of the Holder (any such assignment or transfer
shall be null and void if the Company does not obtain the prior signed written consent of the Holder). This Warrant or any of
the severable rights and obligations inuring to the benefit of or to be performed by Holder hereunder may be assigned by Holder
to a third party, in whole or in part, without the need to obtain the Company’s consent thereto.

 

8. NOTICES.
Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance
with the notice provisions contained in the Purchase Agreement. The Company shall provide the Holder with prompt written notice
(i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation of such adjustment
and (ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend
or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any stock or other securities
directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock or other property, pro rata
to the holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution
or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with
such notice being provided to the Holder.

 

9. AMENDMENT
AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively
or prospectively) only with the written consent of the Company and the Holder.

 

    6

     

    

 

10. GOVERNING
LAW AND VENUE. This Warrant shall be governed by and construed in accordance with the laws of the State of Nevada without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Warrant shall be brought only in the state courts located in the Commonwealth of Massachusetts or in the federal courts
located in the Commonwealth of Massachusetts. The parties to this Warrant hereby irrevocably waive any objection to jurisdiction
and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based
upon forum non conveniens. THE BORROWER HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST,
A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION
CONTEMPLATED HEREBY. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees
and costs. In the event that any provision of this Warrant or any other agreement delivered in connection herewith is invalid
or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may
prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.
Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding
in connection with this Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

11. ACCEPTANCE.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained
herein.

 

12. CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a) “Nasdaq”
means www.Nasdaq.com.

 

(b) “Closing
Sale Price” means, for any security as of any date, (i) the last closing trade price for such security on the Principal
Market, as reported by Nasdaq, or, if the Principal Market begins to operate on an extended hours basis and does not designate
the closing trade price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported by Nasdaq,
or (ii) if the foregoing does not apply, the last trade price of such security in the over-the-counter market for such security
as reported by Nasdaq, or (iii) if no last trade price is reported for such security by Nasdaq, the average of the bid and ask
prices of any market makers for such security as reported by the OTC Markets. If the Closing Sale Price cannot be calculated for
a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the
fair market value as mutually determined by the Company and the Holder. All such determinations to be appropriately adjusted for
any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

(c) “Common
Stock” means the Company’s common stock, and any other class of securities into which such securities may hereafter
be reclassified or changed.

 

(d) “Common
Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time
Common Stock, including without limitation any debt, preferred stock, rights, options, warrants or other instrument that is at
any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

(e) “Dilutive
Issuance” is any issuance of Common Stock or Common Stock Equivalents described in Section 2(b) above; provided, however,
that a Dilutive Issuance shall not include any Exempt Issuance.

 

    7

     

    

 

(f) “Exempt
Issuance” means the issuance of all shares of Common Stock and Common Stock Equivalents actually issued by the Company
on or after the date hereof: (A) upon conversion of this Warrant; (B) upon issuance and/or conversion of the Promissory Note contemplated
by the Purchase Agreement; (C) pursuant to the exercise of options, warrants or other common stock purchase rights issued (or
to be issued) to employees, officers or directors of, or (so long as the value or exercise price of such issuances of securities
is no less than $1.00 per share) consultants or advisors to, the Company pursuant to any stock purchase plan, stock option plan,
equity incentive plan or other plan or arrangement approved by the Board of Directors (or the Compensation Committee thereof)
at any time; (D) pursuant to the exercise of options, warrants or any evidence of indebtedness, shares of capital stock (other
than Common Stock) or other securities convertible into or exchangeable for Common Stock outstanding as of the date of the issuance
of this Warrant and as disclosed in the Company’s public filings with the SEC; (E) in connection with the acquisition of
all or part of another entity by stock acquisition, merger, consolidation or other reorganization, or by the purchase of all or
part of the assets of such other entity (including securities issued to persons formerly employed by such other entity and subsequently
hired by the Company and to any brokers or finders in connection therewith); (F) in connection with strategic transactions approved
by the Board of Directors (provided such transactions is not primarily for the purpose of raising capital); (G) to bona fide commercial
partners, or lessors in connection with credit arrangements, equipment financings or similar transactions approved by the Board
of Directors; (H) in connection with the Company’s acquisition, joint-venture, licensing or business transaction of intellectual
property assets from any individuals or entities approved by the Board of Directors; and (i) shares of Common Stock issued pursuant
to real property leasing arrangement from a bank approved by the Board of Directors of the Company.

 

(g) “Principal
Market” means the primary national securities exchange on which the Common Stock is then traded.

 

(h) “Market
Price” means the average of the previous VWAP for the 5 trading days immediately prior to the date of the respective
Exercise Notice.

 

(i) “Trading
Day” means (i) any day on which the Common Stock is listed or quoted and traded on its Principal Market, (ii) if the
Common Stock is not then listed or quoted and traded on any national securities exchange, then a day on which trading occurs on
any over-the-counter markets, or (iii) if trading does not occur on the over-the-counter markets, any Business Day.

 

*
* * * * * *

 

    8

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the Issuance Date set forth above.

 

	 	BRAIN SCIENTIFIC, INC.
	 	 
	 	/s/ Boris Goldstein
	 	Name:	Boris Goldstein
	 	Title:	Chairman

 

     

     

    

 

EXHIBIT
A

 

EXERCISE
NOTICE

 

(To
be executed by the registered holder to exercise this Common Stock Purchase Warrant)

 

The
Undersigned holder hereby exercises the right
to purchase _________________ of the shares of Common Stock (“Warrant Shares”) of BRAIN SCIENTIFIC, Inc., a Nevada
corporation (the “Company”), evidenced by the attached copy of the Common Stock Purchase Warrant (the “Warrant”).
Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

		1.	Form
                                         of Exercise Price. The Holder intends that payment of the Exercise Price shall be
                                         made as (check one):

 

		☐	a
                                         cash exercise with respect to _________________ Warrant Shares; or

 

		☐	by
cashless exercise pursuant to the Warrant.

 

		2.	Payment
                                         of Exercise Price. If cash exercise is selected above, the holder shall pay the applicable
                                         Aggregate Exercise Price in the sum of $___________________ to the Company in accordance
                                         with the terms of the Warrant.

 

		3.	Delivery
                                         of Warrant Shares. The Company shall deliver to the holder __________________ Warrant
                                         Shares in accordance with the terms of the Warrant.

 

	Date:	 	 

 

	 	 
	 	(Print Name of Registered Holder)
	 	 
	 	By:	 
	 	Name:	      
	 	Title:	 

 

    A-1

     

    

 

EXHIBIT
B

 

ASSIGNMENT
OF WARRANT

 

(To
be signed only upon authorized transfer of the Warrant)

 

For
Value Received, the undersigned hereby sells,
assigns, and transfers unto ____________________ the right to purchase _______________ shares of common stock of BRAIN SCIENTIFIC,
Inc., to which the within Common Stock Purchase Warrant relates and appoints ____________________, as attorney-in-fact, to transfer
said right on the books of BRAIN SCIENTIFIC, Inc. with full power of substitution and re-substitution in the premises. By accepting
such transfer, the transferee has agreed to be bound in all respects by the terms and conditions of the within Warrant.

 

	Dated:	 	 

 

	 	 
	 	(Signature) *
	 	 
	 	 
	 	(Name)
	 	 
	 	 
	 	(Address)
	 	 
	 	 
	 	(Social Security or Tax Identification No.)

 

		*	The
signature on this Assignment of Warrant must correspond to the name as written upon the face of the Common Stock Purchase Warrant
in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation, partnership,
trust or other entity, please indicate your position(s) and title(s) with such entity.

 

 

B-1Exhibit
10.1

 

CERTIFICATE
OF DESIGNATION OF

 

XXStream
Entertainment, Inc.

 

Pursuant
to Section 78.1955 of the Nevada Revised Statutes

 

SERIES
A PREFERRED STOCK

 

On
behalf of XXStream Entertainment, Inc., a Nevada corporation (the “Corporation”), the undersigned hereby certifies
that the following resolution has been duly adopted by the board of directors of the Corporation (the “Board”):

 

RESOLVED,
that, pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Corporation
(the “Articles of Incorporation”), there hereby is created, out of the Nine Billion Common Shares (9,000,000,000)
shares of Common stock, par value $0.001 per share, of the Corporation authorized by the Corporation’s Articles of Incorporation
(“Preferred Stock”), Series A Preferred Stock, consisting of One Hundred Million (100,000,000) shares, which
series shall have the following powers, designations, preferences and relative participating, optional and other special rights,
and the following qualifications, limitations and restrictions:

The
specific powers, preferences, rights and limitations of the Series A Preferred Stock are as follows:

 

1. Dividend
Provisions. Subject to the rights of any existing series of Preferred Stock or to the rights of any series of Preferred
Stock which may from time to time hereafter come into existence, the holders of shares of Series A Preferred Stock shall be entitled
to receive dividends, out of any assets legally available therefor, upon any payment of any dividend (payable other than in Common
Stock or other securities and rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional
shares of Common Stock of the Corporation) on the Common Stock of the Corporation, as and if declared by the Board of Directors,
as if the Series A Preferred Stock had been converted into Common Stock.

 

2.
Liquidation Preference.

 

(a) In
the event of any liquidation, dissolution or winding up of the Corporation, either voluntary or involuntary, subject to the rights
of any existing series of Preferred Stock or to the rights of any series of Preferred Stock which may from time to time hereafter
come into existence, the holders of the Series A Preferred Stock shall be entitled to receive, prior and in preference to any
distribution of any of the assets of the Corporation to the holders of Common Stock by reason of their ownership thereof, an amount
per share equal to the price per share actually paid to the Corporation upon the initial issuance of the Series A Preferred Stock
(each, the “the Original Issue Price”) for each share of Series A Preferred Stock then held by them, plus declared
but unpaid dividends. Unless the Corporation can establish a different Original Issue Price in connection with a particular sale
of Series A Preferred Stock, the Original issue price shall be $0.001 per share for the Series A Preferred Stock. If, upon the
occurrence of any liquidation, dissolution or winding up of the Corporation, the assets and funds thus distributed among the holders
of the Series A Preferred Stock shall be insufficient to permit the payment to such holders of the full aforesaid preferential
amounts, then, subject to the rights of any existing series of Preferred Stock or to the rights of any series of Preferred Stock
which may from time to time hereafter come into existence, the entire assets and funds of the corporation legally available for
distribution shall be distributed ratably among the holders of the each series of Preferred Stock in proportion to the preferential
amount each such holder is otherwise entitled to receive.

 

     

     

    

 

(b) Upon
the completion of the distribution required by Section 2(a) above and any other distribution that may be required with respect
to the rights of any existing series of Preferred Stock or to the rights of any series of Preferred Stock which may from time
to time hereafter come into existence, if assets remain in the Corporation, the remaining assets shall be distributed to the holders
of the Common Stock until such time as the holders of the Common stock shall have received a return of the capital originally
contributed thereby. Thereafter, if assets remain in the Corporation, all remaining assets shall be distributed to all holders
of Common Stock and to each series of Preferred Stock, pro rata based on the number of shares of Common Stock held by each
(assuming conversion of all such Preferred Stock into Common Stock).

 

(c) For
purposes of this Section 2, a liquidation, dissolution or winding up of the Corporation shall be deemed to be occasioned by, or
to include, (i) the acquisition of the Corporation by another entity by means of any transaction or series of related transactions
(including, without limitation, any reorganization, merger or consolidation, but excluding any merger effected exclusively for
the purpose of changing the domicile of the Corporation); or (ii) a sale of all or substantially all of the assets of the Corporation,
unless the Corporation’s stockholders of record as constituted immediately prior to such acquisition or sale will,
immediately after such acquisition or sale (by virtue of securities issued as consideration for the Corporation’s acquisition
or sale or otherwise) hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity in approximately
the same relative percentages after such acquisition or sale as before such acquisition or sale.

 

(d) In
any of the events specified in (c) above, if the consideration received by the corporation is other than cash, its value will
be deemed its fair market value. Any securities shall be valued as follows:

 

(i) Securities
not subject to investment letter or other similar restrictions on free marketability:

 

(A) If
traded on a securities exchange, the value shall be deemed to be the average of the closing prices of the securities on such exchange
over the thirty-day period ending three (3) days prior to the closing;

 

(B) If
actively traded over-the-counter, the value shall be deemed to be the average of the closing bid or sale prices (whichever is
applicable) over the thirty-day period ending three (3) days prior to the closing; and

 

    2

     

    

 

(C) If
there is no active public market, the value shall be the fair market value thereof, as determined in good faith by the Board of
Directors.

 

(ii) The
method of valuation of securities subject to investment letter or other restrictions on free marketability (other than restrictions
arising solely by virtue of a stockholder’s status as an affiliate or former affiliate) shall be to make an appropriate
discount from the market value determined as above in (i) (A), (B) or (C) to reflect the approximate fair market value thereof,
as mutually determined by the Corporation and the holders of at least a majority of the voting power of all then outstanding shares
of Preferred Stock.

 

(iii) In
the event the requirements of Section 2(c) are not complied with, the Corporation shall forthwith either:

 

(A) cause
such closing to be postponed until such time as the requirements of this Section 2 have been complied with; or

 

(B) cancel
such transaction, in which event the rights, preferences and privileges of the holders of the Series A Preferred Stock shall revert
to and be the same as such rights, preferences and privileges existing immediately prior to the date of the first notice referred
to in Section 2(c)(iv) hereof.

 

(iv) The
Corporation shall give each holder of record of Series A Preferred Stock written notice of such impending transaction not later
than twenty (20) days prior to the stockholders’ meeting called to approve such transaction, or twenty (20) days prior to
the closing of such transaction, whichever is earlier, and shall also notify such holders in writing of the final approval of
such transaction. The first of such notices shall describe the material terms and conditions of the impending transaction and
the provisions of this Section 2, and the corporation shall thereafter give such holders prompt notice of any material changes.
The transaction shall in no event take place sooner than twenty (20) days after the corporation has given the first notice provided
for herein or sooner than ten (10) days after the corporation has given notice of any material changes provided for herein; provided,
however, that time periods set forth in this paragraph may be shortened upon the written consent of the holders of Series A Preferred
Stock that are entitled to such notice rights or similar notice rights and that represent at least a majority of the voting power
of all then outstanding shares of such Series A Preferred Stock.

 

3. Redemption.
The Series A Preferred Stock shares are non- redeemable other than upon the mutual agreement of the Company and the holder of
shares to be redeemed, and even in such case only to the extent permitted by this Certificate of Designation, the Corporation’s
Articles of Incorporation and applicable law.

 

4. Conversion.
The holders of the Series A Preferred Stock, shall have conversion rights as follows (the “Conversion Rights”):

 

(a) Right
to Convert. Subject to Section 4(c), each share of Series A Preferred Stock shall be convertible, at the option of the
holder thereof, at any time after the date of issuance of such share, at the office of the Corporation or any transfer agent for
such stock, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing the Original
Issue Price of the Series A Preferred Stock by the Series A Conversion Price applicable to such share, determined as hereafter
provided, in effect on the date the certificate is surrendered for conversion. The initial Series A Conversion ratio shall be
100 Common Shares per each Preferred Share.

 

    3

     

    

 

(b) Automatic
Conversion. Each share of Series A Preferred Stock shall automatically be converted into shares of Common Stock at the
applicable Series A Conversion Price in effect for such share immediately upon the earlier of (i) except as provided below in
Section 4(c), the Corporation’s sale of its Common Stock in a public offering pursuant to a registration statement under
the Securities Act of 1933, as amended; (ii) a liquidation, dissolution or winding up of the Corporation as defined in section
2(c) above but subject to any liquidation preference required by section 2(a) above; or (iii) the date specified by written consent
or agreement of the holders of a majority of the then outstanding shares of Series A Preferred Stock.

 

(c) Mechanics
of Conversion. Before any holder of Series A Preferred Stock shall be entitled to convert the same into shares of Common
Stock, such holder shall surrender the certificate or certificates therefor, duly endorsed, at the office of the Corporation or
of any transfer agent for the Series A Preferred Stock, and shall give written notice to the Corporation at its principal corporate
office, of the election to convert the same and shall state therein the name or names in which the certificate or certificates
for shares of Common Stock are to be issued. The Corporation shall, as soon as practicable thereafter, issue and deliver at such
office to such holder of Series A Preferred Stock, or to the nominee or nominees of such holder, a certificate or certificates
for the number of shares of Common Stock to which such holder shall be entitled as aforesaid. Such conversion shall be deemed
to have been made immediately prior to the close of business on the date of such surrender of the shares of Series A Preferred
Stock to be converted, and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion
shall be treated for all purposes as the record holder or holders of such shares of Common Stock as of such date. If the conversion
is in connection with an underwritten offering of securities registered pursuant to the Securities Act of 1933, the conversion
may, at the option of any holder tendering Series A Preferred Stock for conversion, be conditioned upon the closing with the underwriters
of the sale of securities pursuant to such offering, in which event the person(s) entitled to receive Common Stock upon conversion
of such Series A Preferred Stock shall not be deemed to have converted such Series A Preferred Stock until immediately prior to
the closing of such sale of securities.

 

(d) Conversion
Price Adjustments of Preferred Stock for Certain Splits. The Series A Conversion Price shall be subject to adjustment
from time to time as follows:

 

(i) In
the event the corporation should at any time or from time to time after the purchase date with respect to any share of Series
A Preferred Stock fix a record date for the effectuation of a split or subdivision of the outstanding shares of Common Stock or
the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in additional shares
of Common Stock or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly,
additional shares of Common Stock (hereinafter referred to as “Common Stock Equivalents”) without payment of
any consideration by such holder for the additional shares of Common Stock or the Common Stock Equivalents (including the additional
shares of Common Stock issuable upon conversion or exercise thereof), then, as of such record date (or the date of such dividend
distribution, split or subdivision if no record date is fixed), the Series A Conversion Price, as the case may be, shall be appropriately
decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased
in proportion to such increase of the aggregate of shares of Common Stock outstanding and those issuable with respect to such
Common Stock Equivalents with the number of shares issuable with respect to Common Stock Equivalents determined from time to time
as provided in Section 4(d)(iii) below.

 

    4

     

    

 

(ii) If
the number of shares of Common Stock outstanding at any time after the purchase date of any shares of Series A Preferred Stock
is decreased by a combination of the outstanding shares of Common Stock, the Series A Conversion Price shall not be increased
or adjusted and the number of shares of Common Stock issuable on conversion of each share of Series A Preferred Stock shall not
be decreased or adjusted.

 

(iii)
The following provisions shall apply for purposes of this Section 4(d):

 

(A)
The aggregate maximum number of shares of Common Stock deliverable upon conversion or exercise of Common Stock Equivalents (assuming
the satisfaction of any conditions to convertibility or exercisability, including, without limitation, the passage of time, but
without taking into account potential antidilution adjustments) shall be deemed to have been issued at the time such Common Stock
Equivalents were issued.

 

(B) In
the event of any change in the number of shares of Common Stock deliverable or in the consideration payable to the Corporation
upon conversion or exercise of such Common Stock Equivalents including, but not limited to, a change resulting from the antidilution
provisions thereof, the Series A Conversion Price, to the extent in any way affected by or computed using such Common Stock Equivalents,
shall be recomputed to reflect such change, but no further adjustment shall be made for the actual issuance of Common Stock or
any payment of such consideration upon the exercise of any such options or rights or the conversion or exchange of such securities.

 

(C) Upon
the termination or expiration of the convertibility or exercisability of any such Common Stock Equivalents, the Series A Conversion
Price, to the extent in any way affected by or computed using such Common Stock Equivalents, shall be recomputed to reflect the
issuance of only the number of shares of Common Stock (and Common Stock Equivalents which remain convertible or exercisable) actually
issued upon the conversion or exercise of such Common Stock Equivalents.

 

(e) Other
Distributions. In the event the Corporation shall declare a distribution payable in securities of other persons, evidences
of indebtedness issued by the Corporation or other persons, assets (excluding cash dividends) or options or rights not referred
to in Section 4(d)(iii), then, in each such case for the purpose of this Section 4(e), the holders of Series A Preferred Stock
shall be entitled to a proportionate share of any such distribution as though they were the holders of the number of shares of
Common Stock of the corporation into which their shares of Series A Preferred Stock are convertible as of the record date fixed
for the determination of the holders of Common Stock of the corporation entitled to receive such distribution.

 

    5

     

    

 

(f) Recapitalizations.
If at any time or from time to time there shall be a recapitalization of the Common Stock (other than a subdivision, combination
or merger or sale of assets transaction provided for elsewhere in this Section 4 or Section 2) provision shall be made so that
the holders of the Series A Preferred Stock shall thereafter be entitled to receive upon conversion of the Series A Preferred
Stock the number of shares of stock or other securities or property of the Company or otherwise, to which a holder of Common Stock
deliverable upon conversion would have been entitled on such recapitalization. In any such case, appropriate adjustment shall
be made in the application of the provisions of this Section 4 with respect to the rights of the holders of the Series A Preferred
Stock after the recapitalization to the end that the provisions of this Section 4 (including adjustment of the Series A Conversion
Price then in effect and the number of shares purchasable upon conversion of the Series A Preferred Stock) shall be applicable
after that event and be as nearly equivalent as practicable.

 

(g) No
Impairment. The Corporation will not, by amendment of its Articles of Incorporation or through any reorganization, recapitalization,
transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek
to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but will
at all times in good faith assist in the carrying out of all the provisions of this Section 4 and in the taking of all such action
as may be necessary or appropriate in order to protect the Conversion Rights of the holders of the Series A Preferred Stock against
impairment.

 

(h)
No Fractional Shares and Certificate as to Adjustments.

 

(i) No
fractional shares shall be issued upon the conversion of any share or shares of the Series A Preferred Stock, and the number of
shares of Common Stock to be issued shall be rounded to the nearest whole share. Whether or not fractional shares are issuable
upon such conversion shall be determined on the basis of the total number of shares of Series A Preferred Stock the holder is
at the time converting into Common Stock and the number of shares of Common Stock issuable upon such aggregate conversion.

 

(ii) Upon
the occurrence of each adjustment or readjustment of the Series A Conversion Price pursuant to this Section 4, the Corporation,
at its expense, shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish
to each holder of Series A Preferred Stock a certificate setting forth such adjustment or readjustment and showing in detail the
facts upon which such adjustment or readjustment is based. The Corporation shall, upon the written request at any time of any
holder of Series A Preferred Stock furnish or cause to be furnished to such holder a like certificate setting forth (A) such adjustment
and readjustment, (B) the Series A Conversion Price for the Series A Preferred Stock at the time in effect, and (C) the number
of shares of Common Stock and the amount, if any, of other property which at the time would be received upon the conversion of
a share of Series A Preferred Stock.

 

    6

     

    

 

(i) Notices
of Record Date. In the event of any taking by the Corporation of a record of the holders of any class of securities for
the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend) or other
distribution, any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities
or property, or to receive any other right, the Corporation shall mail to each holder of Series A Preferred Stock, at least 20
days prior to the date specified therein, a notice specifying the date on which any such record is to be taken for the purpose
of such dividend, distribution or right, and the amount and character of such dividend, distribution or right.

 

(j) Reservation
of Stock Issuable Upon Conversion. The Corporation shall at all times reserve and keep available out of its authorized
but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the shares of the Series A Preferred
Stock, such number of its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding
shares of Series A Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not
be sufficient to effect the conversion of all then outstanding shares of Series A Preferred Stock , in addition to such other
remedies as shall be available to the holder of such Series A Preferred Stock, the Corporation will take such corporate action
as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number
of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite
stockholder approval of any necessary amendment to this Certificate of Incorporation.

 

(k) Notices.
Any notice required by the provisions of this Section 4 to be given to the holders of shares of Series A Preferred Stock shall
be deemed given if deposited in the United States mail, postage prepaid, and addressed to each holder of record at his address
appearing on the books of the Corporation.

 

5. Voting
Rights. The holder of each share of Series A Preferred Stock shall have the right to 100 votes for each share of Common
Stock into which such Series A Preferred Stock could then be converted, on an as-converted basis, and with respect to such vote,
such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and
shall be entitled to notice of any stockholders’ meeting in accordance with the bylaws of the Corporation, and shall be
entitled to vote, together with holders of Common Stock, with respect to any question upon which holders of Common Stock have
the right to vote. Fractional votes shall not, however, be permitted and any fractional voting rights available on an as-converted
basis (after aggregating all shares into which shares of Series A Preferred Stock held by each holder could be converted) shall
be rounded to the nearest whole number (with one-half being rounded upward).

 

6. Protective
Provisions. Subject to the rights of a series of Preferred Stock which may from time to time come into existence, so long
as at least an aggregate of 200,000 shares of Series A Preferred Stock are outstanding, the Corporation shall not without first
obtaining the approval (by vote or written consent, as provided by law) of the holders of at least a majority of the then outstanding
shares of Series A Preferred Stock:

 

(a) amend
or repeal any provision of the Company’s Articles of Incorporation or bylaws if such action would materially and adversely
change the rights, preferences or privileges of the Series A Preferred Stock;

 

    7

     

    

 

(b) increase
or decrease (other than by redemption or conversion) the total number of authorized shares of Series A Preferred Stock; or

 

(c) redeem
shares of Common Stock (other than shares repurchased upon termination of an officer, employee or director pursuant to a restricted
stock purchase agreement).

 

7. Status
of Converted Stock. In the event any shares of Series A Preferred Stock shall be converted pursuant to Section 4 hereof,
the shares so converted shall be canceled and shall not be re-issuable by the corporation.

 

IN
WITNESS WHEREOF, the undersigned has duly signed this Designation as of this 23 day of September, 2020.

 

	XXStream
    Entertainment, Inc., a Nevada Corporation	 
		 	 
	By:	David Lazar	 
	Name:	David Lazar	 
	Title:  	President	 

 

 

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]